ReproCELL Inc.

History

Year	Detail
2003	REPROCELL is a biotech company established in 2003 based on technologies developed by Professor Nakatsuji at Kyoto University.
2004	The company started to commercialize Nanog antibodies (human, mouse).
2010	The company moved its headquarters and laboratory to Yokohama.
2011	The company established a subsidiary, REPROCELL USA, Ltd., in Maryland, U.S.
2012	The company established an agreement for sales collaboration with PerkinElmer Japan Co., Ltd. regarding the human iPS cells model for Alzheimer’s disease.
2013	The company collaborated with Takara Bio, Inc. for custom-made disease model cells.
2014	The company acquired 3D cell culture company Reinnervate Ltd. to produce drug toxicity, neuroscience, and cancer research tools.
2014	The company acquired BioServe Inc. of Maryland, USA, to add BioServe’s preclinical molecular services to its genotyping services.
2015	REPROCELL Inc. acquired the Scottish life sciences company Biopta to expand its drug discovery services.
2017	The company partnered with Fox Chase Medical Center (Philadelphia, U.S.A.) to accelerate biomarker and genetic discovery.
2017	The company collaborated with Q Therapeutics, Inc., a developer of clinical-stage cell therapies for central nervous system (CNS) disease and injury, to develop new iPS cell (IPSC) therapies for central nervous system (CNS) diseases.
2019	REPROCELL Inc. formed a joint venture with Fox Chase Cancer Center to begin operations on biosample repositories.
2021	REPROCELL launched a PCR Testing Service for COVID-19 in collaboration with DNAFORM Inc., a Japanese start-up company.
2023	The company partnered with Histocell and started offering CDMO services to manufacture Advanced Therapies Medicinal Products (ATMPs) generated from mesenchymal stem cells (MSC).